Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Boulware

Showing results (311-320 of 350) with videos related to

Pageof 35
Sort By:
The Lancet. Global Health|April 27, 2025
Personalised risk-prediction tools for cryptococcal meningitis mortality to guide treatment stratification in sub-Saharan Africa: a prognostic modelling study based on pooled analysis of two randomised controlled trialsThomas H A Samuels, Sile F Molloy, David S Lawrence, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 22, 2023
Oral Lipid Nanocrystal Amphotericin B for Cryptococcal Meningitis: A Randomized Clinical TrialDavid R Boulware, Mucunguzi Atukunda, Enock Kagimu, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 4, 2026
Metformin on the Presence of COVID-19 Symptoms 6 Months after Infection: The ACTIV-6 Randomized Clinical TrialCarolyn T Bramante, Thomas G Stewart, David R Boulware, et al.
JAMA|October 21, 2022
Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical TrialSusanna Naggie, David R Boulware, Christopher J Lindsell, et al.
Open Forum Infectious Diseases|April 8, 2022
Vaccination Against SARS-CoV-2 Is Associated With a Lower Viral Load and Likelihood of Systemic SymptomsCarolyn T Bramante, Jennifer L Proper, David R Boulware, et al.
Trials|January 16, 2019
Correction to: AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority TrialDavid S Lawrence, Nabila Youssouf, Síle F Molloy, et al.
Medrxiv : the Preprint Server for Health Sciences|August 20, 2025
Metformin on the Presence of COVID-19 Symptoms Over 6 Months: The ACTIV-6 Randomized Clinical TrialCarolyn T Bramante, Thomas G Stewart, David R Boulware, et al.
Medrxiv : the Preprint Server for Health Sciences|December 23, 2022
Effect of Ivermectin 600 μg/kg for 6 days vs Placebo on Time to Sustained Recovery in Outpatients with Mild to Moderate COVID-19: A Randomized Clinical TrialSusanna Naggie, David R Boulware, Christopher J Lindsell, et al.
Trials|November 25, 2018
AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority TrialDavid S Lawrence, Nabila Youssouf, Síle F Molloy, et al.
Medrxiv : the Preprint Server for Health Sciences|January 4, 2023
Outpatient treatment of Covid-19 with metformin, ivermectin, and fluvoxamine and the development of Long Covid over 10-month follow-upCarolyn T Bramante, John B Buse, David Liebovitz, et al.
Pageof 35

Showing results (311-320 of 350) with videos related to

Sort By:
Pageof 35
The Lancet. Global Health|April 27, 2025
Personalised risk-prediction tools for cryptococcal meningitis mortality to guide treatment stratification in sub-Saharan Africa: a prognostic modelling study based on pooled analysis of two randomised controlled trialsThomas H A Samuels, Sile F Molloy, David S Lawrence, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 22, 2023
Oral Lipid Nanocrystal Amphotericin B for Cryptococcal Meningitis: A Randomized Clinical TrialDavid R Boulware, Mucunguzi Atukunda, Enock Kagimu, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 4, 2026
Metformin on the Presence of COVID-19 Symptoms 6 Months after Infection: The ACTIV-6 Randomized Clinical TrialCarolyn T Bramante, Thomas G Stewart, David R Boulware, et al.
JAMA|October 21, 2022
Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical TrialSusanna Naggie, David R Boulware, Christopher J Lindsell, et al.
Open Forum Infectious Diseases|April 8, 2022
Vaccination Against SARS-CoV-2 Is Associated With a Lower Viral Load and Likelihood of Systemic SymptomsCarolyn T Bramante, Jennifer L Proper, David R Boulware, et al.
Trials|January 16, 2019
Correction to: AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority TrialDavid S Lawrence, Nabila Youssouf, Síle F Molloy, et al.
Medrxiv : the Preprint Server for Health Sciences|August 20, 2025
Metformin on the Presence of COVID-19 Symptoms Over 6 Months: The ACTIV-6 Randomized Clinical TrialCarolyn T Bramante, Thomas G Stewart, David R Boulware, et al.
Medrxiv : the Preprint Server for Health Sciences|December 23, 2022
Effect of Ivermectin 600 μg/kg for 6 days vs Placebo on Time to Sustained Recovery in Outpatients with Mild to Moderate COVID-19: A Randomized Clinical TrialSusanna Naggie, David R Boulware, Christopher J Lindsell, et al.
Trials|November 25, 2018
AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority TrialDavid S Lawrence, Nabila Youssouf, Síle F Molloy, et al.
Medrxiv : the Preprint Server for Health Sciences|January 4, 2023
Outpatient treatment of Covid-19 with metformin, ivermectin, and fluvoxamine and the development of Long Covid over 10-month follow-upCarolyn T Bramante, John B Buse, David Liebovitz, et al.
Pageof 35